Madison-based Exact Sciences narrowed its losses for the quarter ending Sept. 30, compared to the same quarter in 2012. The company’s net loss was reported as $11.2 million (16 cents/share) on revenues of $1 million. A year ago, the company reported net losses of $13 million (21 cents/share) on revenues of $1 million.
Exact Sciences is awaiting FDA approval on its stool-based test for colorectal cancer.
